Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IRON CLAD: Can Iron Lessen Anemia Due to cancer and chemotherapy: A multicenter, randomized, double-blinded, controlled study to investigate the efficacy and safety of Injectafer (ferric carboxymaltose injection) in adults

Next Previous
Search
Trial Profile

IRON CLAD: Can Iron Lessen Anemia Due to cancer and chemotherapy: A multicenter, randomized, double-blinded, controlled study to investigate the efficacy and safety of Injectafer (ferric carboxymaltose injection) in adults

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Chemotherapy-induced anaemia
  • Focus Therapeutic Use
  • Acronyms IRON CLAD
  • Sponsors American Regent; Luitpold Pharmaceuticals

    • Most Recent Events

    • 01 Dec 2021 Results published in the American Journal of Hematology
    • 06 Nov 2019 Status changed from active, no longer recruiting to completed, according to results released in 61st Annual Meeting and Exposition of the American Society of Hematology
    • 06 Nov 2019 Primary endpoint (Percentage of patients with a decrease in Hgb 0.5 g/dL from baseline to Week 18) has been met, according to results released in 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top